Pepiniere Sante Cochin
29 rue du Faubourg Saint Jacques
69 articles with PHARNEXT
Biotech and pharma companies tap new members of executive leadership teams and boards.
Pharnext Announces the Apppointment of Peter Collum as Chief Financial Officer and Chief Business Officer
Pharnext SA announced the appointment of Peter Collum as Chief Financial Officer and Chief Business Officer.
Pharnext SA announced its financial results for the fiscal year ended December 31st, 2018.
Pharnext Announces FDA Fast Track Designation for PLEODRUG(TM) PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A
Pharnext SA announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of PXT3003 for the treatment of patients with Charcot-Marie-Tooth disease Type 1A.
Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer
Pharnext SA announced the appointment of Susanne Dorn, M.Sc., as Chief Regulatory Officer and Serge Fitoussi, M.D., M.Sc., as Chief Medical Officer
Pharnext SA announced today its financial results for first-half 2018.
Pharnext Announces Positive Topline Results from Pivotal Phase 3 Trial of PXT3003 for Treatment of Charcot-Marie-Tooth Type 1A Disease
Higher dose met primary endpoint, the Overall Neuropathy Limitation Scale (ONLS), with statistical significance (p = 0.008)
Vitaccess and Pharnext SA today announced the launch of an international study on Charcot Marie Tooth disease (CMT) using a bespoke digital app named CMT&Me.
Pharnext SA announced the cooptation of David Stout as an independent Director of Pharnext.
This agreement paves the way for the submission of a marketing authorization application in Europe
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 2018
PHARNEXT SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018.
Pharnext SA today announced that PXT3003 was granted priority review for Charcot-Marie-Tooth Type 1A disease (CMT1A) by the China Food and Drug Administration (CFDA).
Pharnext SA announced a financing of up to €20 million through a bond loan with IPF Partners, one of the top providers of alternative financings in the healthcare sector.
Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences
Pharnext SA today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.
Pharnext SA announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO).
Pharnext SA announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference.
Pharnext SA reported its financial and operational results for the year ended December 31, 2017.
March 29, 2018 15:45 UTC Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference PARIS--( BUSINESS WIRE )-- Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a c
Pharnext's Pivotal Phase III Trial PLEO-CMT to be Featured at the 22nd Edition of the Francophone Peripheral Nerve Society Conference
The gathering will take place on January 26-27, 2018 in Paris.
He is replacing Jacques Attali for the remainder of the term, until the Annual Shareholder’s meeting is called to approve the 2018 financial statements.